原发性与术后立体定向放射外科治疗肢端肥大症的多中心匹配队列研究
该多中心匹配队列研究比较了原发性与术后立体定向放射外科(SRS)治疗肢端肥大症的效果。原发性SRS队列26例按1:2匹配术后SRS队列52例,中位随访66.4个月。两组在肿瘤控制、内分泌缓解、生化复发、无复发生存及垂体功能减退方面均无显著差异,原发性SRS显示出合理的获益-风险比。
要点
- 原发性SRS后2年和5年内分泌缓解率分别为20%和42%。
- SRS前IGF-1水平较低预测初始内分泌缓解(p=0.03)。
- SRS边缘剂量较低预测初始缓解后的生化复发(p=0.01)。
核心结论
- 对于无法切除的肢端肥大症患者,原发性SRS具有合理的获益-风险比,且与内分泌可比的手术后SRS患者结局相似。
研究设计与样本
- 多中心匹配队列研究,基于国际放射外科研究基金会数据库398例肢端肥大症患者,原发性SRS队列26例按1:2匹配术后SRS队列52例,中位随访66.4个月。
主要发现
- 原发性SRS队列2年和5年内分泌缓解率分别为20%和42%。
- Cox模型显示SRS前较低的IGF-1水平预测初始内分泌缓解(p=0.03),较低的SRS边缘剂量预测初始缓解后的生化复发(p=0.01)。
- 匹配队列间肿瘤影像学控制率(p=0.34)、初始内分泌缓解率(p=0.23)、初始缓解后生化复发率(p=0.33)、无复发生存率(p=0.32)及垂体功能减退率(p=0.67)均无差异。
临床怎么用
- 对于不能或不愿接受手术的特定肢端肥大症患者,可考虑原发性SRS联合潜伏期内科治疗作为手术替代方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The role of primary stereotactic radiosurgery (SRS) in patients with medically refractory acromegaly who are not operative candidates or who refuse resection is poorly understood. The aim of this multicenter, matched cohort study was to compare the outcomes of primary versus postoperative SRS for acromegaly. METHODS: The authors reviewed an International Radiosurgery Research Foundation database of 398 patients with acromegaly who underwent SRS and categorized them into primary or postoperative cohorts. Patients in the primary SRS cohort were matched, in a 1:2 ratio, to those in the postoperative SRS cohort, and the outcomes of the 2 matched cohorts were compared. RESULTS: The study cohort comprised 78 patients (median follow-up 66.4 months), including 26 and 52 in the matched primary and postoperative SRS cohorts, respectively. In the primary SRS cohort, the actuarial endocrine remission rates at 2 and 5 years were 20% and 42%, respectively. The Cox proportional hazards model showed that a lower pre-SRS insulin-like growth factor-1 level was predictive of initial endocrine remission (p = 0.03), whereas a lower SRS margin dose was predictive of biochemical recurrence after initial remission (p = 0.01). There were no differences in the rates of radiological tumor control (p = 0.34), initial endocrine remission (p = 0.23), biochemical recurrence after initial remission (p = 0.33), recurrence-free survival (p = 0.32), or hypopituitarism (p = 0.67) between the 2 matched cohorts. CONCLUSIONS: Primary SRS has a reasonable benefit-to-risk profile for patients with acromegaly in whom resection is not possible, and it has similar outcomes to endocrinologically comparable patients who undergo postoperative SRS. SRS with medical therapy in the latent period can be used as an alternative to surgery in selected patients who cannot or do not wish to undergo resection.
引用
- Mohammed N, Ding D, Hung YC, et al. Primary versus postoperative stereotactic radiosurgery for acromegaly: a multicenter matched cohort study. J Neurosurg. 2019. PMID: 31026829. doi:10.3171/2019.1.JNS183398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。